Locally‑advanced unresected uterine leiomyosarcoma with triple‑modality treatment combining radiotherapy, chemotherapy and hyperthermia: A case report

Shirafuji,Aya; Shinagawa,Akiko; Kurokawa,Tetsuji; Yoshida,Yoshio

doi:10.3892/ol.2014.2193

Locally‑advanced unresected uterine leiomyosarcoma with triple‑modality treatment combining radiotherapy, chemotherapy and hyperthermia: A case report

Authors:
- Aya Shirafuji
- Akiko Shinagawa
- Tetsuji Kurokawa
- Yoshio Yoshida
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Faculty of Medical Sciences, University of Fukui, Fukui, Japan
Published online on: May 28, 2014 https://doi.org/10.3892/ol.2014.2193
Pages: 637-641

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Advanced uterine leiomyosarcoma (LMS) is a rare and extremely aggressive disease. In patients with advanced and unresected uterine LMS, multidisciplinary therapy is the best treatment option, although no consensus exists on the efficacy of the treatment. The present study describes the case of a 41‑year‑old female who underwent laparotomy due to a large uterine tumor. Exploratory laparotomy revealed a large tumor that had extended from the pelvic wall to the outside of the pelvis and then invaded the colon. Large residual tumors remained present in the pelvis following suboptimal debulking surgery. Subsequent to surgery, the patient was treated with adjuvant radiotherapy, followed by chemotherapy with regional whole pelvis hyperthermia (HT). Computed tomography revealed stable disease prior and subsequent to combination treatment. While treatment was being administered for third/fourth‑degree burns and subcutaneous fatty necrosis, the patient developed multi‑organ failure and succumbed. The present case report describes the potential for using a combination of chemotherapy, HT and radiotherapy in patients with LMS. The development of an effective protocol is required for the administration of chemotherapy, HT and radiotherapy in patients with advanced unresected LMS.

View Figures

View References

1	Park JY, Park SK, Kim DY, et al: The impact of tumor morcellation during surgery on the prognosis of patients with apparently early uterine leiomyosarcoma. Gynecol Oncol. 122:255–259. 2011.
2	Leitao MM Jr, Zivanovic O, Chi DS, et al: Surgical cytoreduction in patients with metastatic uterine leiomyosarcoma at the time of initial diagnosis. Gynecol Oncol. 125:409–413. 2012.
3	Svancárová L, Blay JY, Judson IR, et al: Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 38:556–559. 2002.
4	Okuno S, Edmonson J, Mahoney M, et al: Phase II trial of gemcitabine in advanced sarcomas. Cancer. 94:3225–3229. 2002.
5	Gallup DG, Blessing JA, Andersen W and Morgan MA; Gynecologic Oncology Group Study. Evaluation of paclitaxel in previously treated leiomyosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol. 89:48–51. 2003.
6	Garcia-Carbonero R, Supko JG, Manola J, et al: Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol. 22:1480–1490. 2004.
7	Smith HO, Blessing JA and Vaccarello L: Trimetrexate in the treatment of recurrent or advanced leiomyosarcoma of the uterus: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 84:140–144. 2002.
8	Rose PG, Blessing JA, Soper JT and Barter JF: Prolonged oral etoposide in recurrent or advanced leiomyosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol. 70:267–271. 1998.
9	Slayton RE, Blessing JA, Angel C and Berman M: Phase II trial of etoposide in the management of advanced and recurrent leiomyosarcoma of the uterus: a Gynecologic Oncology Group Study. Cancer Treat Rep. 71:1303–1304. 1987.
10	Asbury R, Blessing JA, Buller R, et al: Amonafide in patients with leiomyosarcoma of the uterus: a phase II Gynecologic Oncology Group study. Am J Clin Oncol. 21:145–146. 1998.
11	Long HJ III, Blessing JA and Sorosky J: Phase II trial of dacarbazine, mitomycin, doxorubicin, and cisplatin with sargramostim in uterine leiomyosarcoma: a Gynecologic Oncology Group study. Gynecol Oncol. 99:339–342. 2005.
12	Edmonson JH, Blessing JA, Cosin JA, et al: Phase II study of mitomycin, doxorubicin, and cisplatin in the treatment of advanced uterine leiomyosarcoma: a Gynecologic Oncology Group study. Gynecol Oncol. 85:507–510. 2002.
13	Currie J, Blessing JA, Muss HB, Fowler J, Berman M and Burke TW: Combination chemotherapy with hydroxyurea, dacarbazine (DTIC), and etoposide in the treatment of uterine leiomyosarcoma: a Gynecologic Oncology Group study. Gynecol Oncol. 61:27–30. 1999.
14	Sutton G, Blessing JA and Malfetano JH: Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol. 62:226–229. 1996.
15	Hensley ML, Maki R, Venkatraman E, Geller G, Lovegren M, Aghajanian C, Sabbatini P, Tong W, Barakat R and Spriggs DR: Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol. 20:2824–2831. 2002.
16	Hensley ML, Blessing JA, Degeest K, Abulafia O, Rose PG and Homesley HD: Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. Gynecol Oncol. 109:323–328. 2008.
17	Wiedemann GJ, Robins HI, Katschinski DM, et al: Systemic hyperthermia and ICE chemotherapy for sarcoma patients: rationale and clinical status. Anticancer Res. 17:2899–2902. 1997.
18	Pereira Arias AM, Wester JP, Blankendaal M, et al: Multiple organ dysfunction syndrome induced by whole-body hyperthermia and polychemotherapy in a patient with disseminated leiomyosarcoma of the uterus. Intensive Care Med. 25:1013–1016. 1999.
19	Westermann AM, Jones EL, Schem BC, et al: First results of triple-modality treatment combining radiotherapy, chemotherapy, and hyperthermia for the treatment of patients with stage IIB, III, and IVA cervical carcinoma. Cancer. 104:763–770. 2005.
20	Mohamed F, Marchettini P, Stuart OA, et al: Thermal enhancement of new chemotherapeutic agents at moderate hyperthermia. Ann Surg Oncol. 10:463–468. 2003.
21	Reed NS, Mangioni C, Malmström H, et al: Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer. 44:808–818. 2008.